Leadership Team

At NeuPath Health Inc., our leadership team is dedicated to advancing our vision of delivering best-in-class care and innovative solutions to improve the lives of our patients, communities, and stakeholders. Together, they bring extensive expertise, passion, and a shared commitment to improving healthcare access and outcomes across Canada.

Joseph Walewicz - Chief Executive Officer

Mr. Joseph Walewicz was Executive Vice President, Business and Corporate Development of Clementia Pharmaceuticals, a NASDAQ-listed company, from 2017 to 2019 prior to Clementia’s acquisition by Ipsen Pharmaceuticals for US$1 billion in April of 2019. Mr. Walewicz has spent 25 years in biopharma, serving on the board and at the executive level of multiple publicly traded biopharma companies including Clementia Pharmaceuticals, MethylGene (now Mirati Therapeutics Inc.), Warnex Inc. and Paladin Labs, and as a top ranked equities analyst for major banks including CIBC, BMO, Lehman Brothers where he covered publicly traded North American biotechnology, pharmaceuticals, medtech and healthcare services companies. Mr. Walewicz holds a Master of Business Administration, Finance (McGill), as well as a Bachelor of Science, Biochemistry, and a Bachelor of Arts, Economics from Queen’s University. Mr. Walewicz is also a CFA (Chartered Financial Analyst) charterholder and a member of the Licensing Executives Society (LES).
Jeff Zygouras CPA, CA - Chief Financial Officer

Mr. Zygouras joined NeuPath as Corporate Controller in September 2019 and was promoted to Interim Chief Financial Officer in July 2021. Mr. Zygouras has more than 10 years of progressive finance experience including over 7 years with TSX-listed public companies in the health care industry. Prior to NeuPath, Mr. Zygouras served as the Finance Manager at Miravo Healthcare (TSX:MRV)(formerly Nuvo Pharmaceuticals) where he supported the Company through the transformational acquisition of Aralez Pharmaceuticals to become one of the premier specialty pharmaceutical companies in Canada. Prior to working in the healthcare industry, Mr. Zygouras was a member of Ernst & Young Toronto where he completed his designation gaining experience in a variety of industries. Mr. Zygouras is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto.
Stephen Lemieux - President

Mr. Lemieux joined NeuPath as President in May 2025. Mr. Lemieux is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in finance and operations. Prior to joining the Company, Mr. Lemieux held Chief Financial Officer positions at healthcare and biopharmaceutical biotechnology companies, where he guided financial strategies, optimized capital structures and supported significant corporate transactions and sales growth, including; Edesa Biotech, Titan Medical, NeuPath (April 2019 to July 2021), Cipher Pharmaceuticals (where he also served as Interim-CEO during his tenure), Nuvo Pharmaceuticals and Crescita Therapeutics. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto.
Denise Hill - Vice President Western Canada

Ms. Hill joined NeuPath with the acquisition of HealthPointe Medical Centres in February 2021. As Vice President for Western Canada, she is responsible for both operational oversight and for building the NeuPath/HealthPointe brand in Western Canada. Ms. Hill has years of experience leading health industry organizations and providing strategic leadership in the healthcare field. She is the former CEO of HealthPointe and prior to that was Executive Director of a large orthopedic clinic in Edmonton, The Edmonton Bone and Joint Centre. Ms. Hill also previously worked for the Alberta Medical Association and Workers’ Compensation Board in Alberta in the areas of executive consulting and senior leadership. Ms. Hill holds an MBA from Queen’s University and an under graduate degree from the University of Alberta, as well as a Certificate in Occupational Health and Safety.
Geeta Vadgama - Vice President Operations

Ms. Vadgama joined NeuPath as Regional Director in October 2018 and was promoted to Vice President of Operations in January 2024. Ms. Vadgama has more than 10 years of leadership experience in the health care industry. With a strong focus on coaching and training staff for success, Geeta has a proven track record in developing and implementing innovative programs, consulting, and managing complex projects. Prior to NeuPath, Ms. Vadgama served as the CPM Service Director at AIM Health Group.
Grishanth Ram - Vice President, Operations – InMedic Pain Management Centres

Grishanth Ram is a healthcare executive with over 15 years of experience in operations and technology integration. As Vice President of Operations at InMedic Pain Management Centres, he drives efficiency, patient care, and strategic growth.

Previously, he served as CEO, Board Member, and Strategic Advisor for NeuPath Health, where he played a key role in its expansion. As a co-founder of NeuPath Health, he helped shape its vision and strategy.

Mr. Ram holds a bachelor’s degree from DePaul University and an MBA from the University of Fredericton. He also earned a certification from MIT in Artificial Intelligence and its Implications in Business and Strategy, reinforcing his expertise in healthcare innovation.
Sandee Dela Cruz – Vice President, Information Technology

Sandee is an IT executive with over 20 years of experience driving technology innovation and business transformation, including 15+ years in TSX-listed companies. He excels in aligning IT strategies with corporate goals to deliver measurable business value. As Head of IT in the healthcare and advertising industries, Sandee specializes in digital transformation, AI adoption, cybersecurity, and IT-business alignment. He has successfully led major initiatives, including M&As, enterprise implementations, and automation projects. Notably in Q1 2024, Sandee led the IT due diligence for the acquisition of Searchlight Pharma Inc. a Specialty Pharma company by Apotex Canada Inc., Canada’s largest generic drug manufacturer ensuring a seamless transition. Sandee was recognized as a Top 10 Mid-Market CIO by Info-Tech in 2015, 2020, and 2023, ranking him among Canada’s top IT leaders. A strong advocate for AI-driven efficiency and innovation, Sandee serves as Advisory Chair for Seneca College’s technology program, shaping the next generation of IT professionals.

Board of Directors

Daniel Chicoine - Director (Chair)

Mr. Chicoine is currently the Chair of Crescita Therapeutics Inc. (TSX:CTX ), where he oversees the investor relations function, and advises management on certain strategic business development projects from time to time. From March 1, 2016 until April 2, 2018, Mr. Chicoine served as Crescita’s Chairman and Interim Chief Executive Officer, at which time he was succeeded by Mr. Verreault. Mr. Chicoine served as Nuvo Research’s Chairman and Co-CEO and was actively involved in its day-to-day operations from 2004 to 2016 when Crescita became a reporting issuer following the reorganization of Nuvo Research into two separate publicly traded entities, Crescita and Nuvo Pharmaceuticals Inc. Prior to 2004, Mr. Chicoine held various senior executive positions at the Magna International group of companies, including President and Chief Executive Officer and Chief Financial Officer, and was the President of PowerCart Systems Inc., a Markham-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability. Mr. Chicoine is a graduate of the University of Toronto in commerce and is a Chartered Professional Accountant.
Jolyon Burton - Director

Mr. Burton is a co-founder of Bloom Burton & Co. and serves as the firm’s President and Head of Investment Banking. As trusted advisors to boards of directors, management teams, and professional and strategic investors, Jolyon and his team help structure and execute financial and capital markets strategies, mergers and acquisitions or other partnering transactions. The team has been directly involved in financings of over $1 billion as well as mergers and acquisitions transactions valued at more than $2 billion. In the role immediately preceding the co-founding of Bloom Burton, Jolyon served as the Head of Healthcare & Biotechnology Investment Banking at an independent investment dealer. Jolyon started his career in roles that helped internationally focused growth companies, both at Export Development Canada and Global Affairs Canada.

Mr. Burton serves as a Director of Grey Wolf Animal Health. He is a graduate of the University of Waterloo with an Honours Bachelor of Arts in Applied Studies, with a Major in Economics and Specializations in Finance and International Trade and received the Department of Economics award for academic achievement among his graduating class.
Sasha Cucuz - Director

Mr. Cucuz is the Chief Executive Officer of Greybrook Securities, Inc. since 2005, where he directs Greybrook’s capital markets activities across the firm’s focus areas in real estate and healthcare. Operationally, Mr. Cucuz co-manages Greybrook Realty Partners’ business across both its Asset Management and Capital Markets verticals. Mr. Cucuz also serves as the Co-chair of Greybrook’s Advisory Committee for all active limited partnerships which include more than 50 real estate developments with an estimated completion value of approximately $14 billion, and the Co-chair of Greybrook’s investment committee. As the former CEO of Greybrook Health, Mr. Cucuz played a critical role in the launch of Greenbrook TMS and Greybrook’s prior portfolio acquisitions of MacuHealth and Bruder Health Care. He currently serves on the board of Greenbrook TMS, as well as on the boards of a number of Greybrook affiliated companies and the Blu Genes Foundation. After receiving a Bachelor of Arts in Economics from York University in 2000, Sasha went on to play professional hockey for three seasons. Mr. Cucuz began his career at TD Securities and CIBC before founding Greybrook Capital with his partners.
Dan Legault - Director

Dan Legault is currently the Chief Operating Officer of Juniper Genomics. From 2009 to 2024, Mr Legault served as the Chief Executive Officer of Antibe Therapeutics (TSXV:ATE). Trained as a corporate lawyer and as an air force rescue pilot, Mr. Legault’s career has evolved to focus on high-growth, mostly technology-based companies. His CEO-level experience includes organizations specializing in data analytics, IT and consumer marketing. Mr. Legault has served on the boards of directors of International Save the Children and of Green Shield Canada, a leading health benefits administrator. Mr. Legault continues to serve as a board member and advisor to several companies and not-for-profit organizations. Mr. Legault is a member of the Law Society of Upper Canada and the New York State Bar.
Joseph Walewicz - Director

Mr. Joseph Walewicz was Executive Vice President, Business and Corporate Development of Clementia Pharmaceuticals, a NASDAQ-listed company, from 2017 to 2019 prior to Clementia’s acquisition by Ipsen Pharmaceuticals for US$1 billion in April of 2019. Mr. Walewicz has spent 25 years in biopharma, serving on the board and at the executive level of multiple publicly traded biopharma companies including Clementia Pharmaceuticals, MethylGene (now Mirati Therapeutics Inc.), Warnex Inc. and Paladin Labs, and as a top ranked equities analyst for major banks including CIBC, BMO, Lehman Brothers where he covered publicly traded North American biotechnology, pharmaceuticals, medtech and healthcare services companies. Mr. Walewicz holds a Master of Business Administration, Finance (McGill), as well as a Bachelor of Science, Biochemistry, and a Bachelor of Arts, Economics from Queen’s University. Mr. Walewicz is also a CFA (Chartered Financial Analyst) charterholder and a member of the Licensing Executives Society (LES).

Leadership Team

Board of Directors

About

Resources

Clinic Network